Grant: Master's Award: Canada Graduate Scholarships
University of Saskatchewan
$17,500.00
Synthetic Lethality Related to Over-Expression of Telomerase Reverse Transcriptase in a Prostate Cancer Model
FY 2021-22
Summary
Telomeres are regions of repetitive nucleotide sequences located at the end of chromosomes to help preserve the integrity of the genome. These sequences are maintained by Telomerase, a large enzyme composed of an enzymatic component (hTERT) and an RNA component (hTERC). Telomerase activity is normally limited to embryonic gestation with essentially no activity in somatic cells. Consequently, telomeres shorten with age and cellular division which leads to senescence. In many cancers, including prostate, telomerase is highly expressed and preserves their telomeres which contributes to their longevity. As the rate-limiting factor for this enzyme is the expression of hTERT, its potential as a target for anti-tumor therapy is impressive. Historically, telomerase-targeting activities have been unsuccessful clinically but to bypass their shortfalls, we applied an unbiased genome-wide screen. This screen identified synthetic lethal interactions where inhibition of a gene is lethal only in the setting of hTERT overexpression. This created a shortlist of 30 potential targets which will be evaluated in multiple cell lines, primary cell lines, and xenograft models. Prostate cancer is clinically challenging disease to treat. The most common non-skin cancer in men, it is currently treated through hormonal deprivation therapy. In many cases, the cancer will adapt to resist this therapeutic challenge. Some pharmaceuticals exist to extend the lifespan of these patients, but frequently are insufficient to prevent the cancer progressing into more advanced disease. By using telomerase as a tool to guide therapy, rather than target it directly, we hope to overcome previous shortcomings with novel therapeutic targets in the treatment of prostate cancer.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
467101
Name
Price Jared D
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Synthetic Lethality Related to Over-Expression of Telomerase Reverse Transcriptase in a Prostate Cancer Model
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Tumor Therapy; Cancer; Crispr/Cas9; Crpc; Htert; Prostate Cancer; Synthetic Lethal Interactions; Telomerase
Abstract
Telomeres are regions of repetitive nucleotide sequences located at the end of chromosomes to help preserve the integrity of the genome. These sequences are maintained by Telomerase, a large enzyme composed of an enzymatic component (hTERT) and an RNA component (hTERC). Telomerase activity is normally limited to embryonic gestation with essentially no activity in somatic cells. Consequently, telomeres shorten with age and cellular division which leads to senescence. In many cancers, including prostate, telomerase is highly expressed and preserves their telomeres which contributes to their longevity. As the rate-limiting factor for this enzyme is the expression of hTERT, its potential as a target for anti-tumor therapy is impressive. Historically, telomerase-targeting activities have been unsuccessful clinically but to bypass their shortfalls, we applied an unbiased genome-wide screen. This screen identified synthetic lethal interactions where inhibition of a gene is lethal only in the setting of hTERT overexpression. This created a shortlist of 30 potential targets which will be evaluated in multiple cell lines, primary cell lines, and xenograft models. Prostate cancer is clinically challenging disease to treat. The most common non-skin cancer in men, it is currently treated through hormonal deprivation therapy. In many cases, the cancer will adapt to resist this therapeutic challenge. Some pharmaceuticals exist to extend the lifespan of these patients, but frequently are insufficient to prevent the cancer progressing into more advanced disease. By using telomerase as a tool to guide therapy, rather than target it directly, we hope to overcome previous shortcomings with novel therapeutic targets in the treatment of prostate cancer.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Price, Jared D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~